Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2010 Dec;120(12):4192-7. doi: 10.1172/JCI45250. Epub 2010 Nov 22.

Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Author information

1
Department of Pediatrics, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, Minneapolis, Minnesota, USA. schleiss@umn.edu

Abstract

The magnitude and durability of immunity to human cytomegalovirus (HCMV) following natural infection is compromised by the presence of immune modulation genes that appear to promote evasion of host clearance mechanisms. Since immunity to HCMV offers limited protection, rational design of effective vaccines has been challenging. In this issue of the JCI, Slavuljica and colleagues employ techniques to genetically modify the highly related mouse CMV (MCMV), in the process generating a virus that was rapidly cleared by NK cells. The virus functioned as a safe and highly effective vaccine. Demonstration of the ability to engineer a safe and highly effective live virus vaccine in a relevant rodent model of CMV infection may open the door to clinical trials of safer and more immunogenic HCMV vaccines.

PMID:
21099107
PMCID:
PMC2993604
DOI:
10.1172/JCI45250
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center